MX2015007193A - Ligando de receptor de neurotensina. - Google Patents

Ligando de receptor de neurotensina.

Info

Publication number
MX2015007193A
MX2015007193A MX2015007193A MX2015007193A MX2015007193A MX 2015007193 A MX2015007193 A MX 2015007193A MX 2015007193 A MX2015007193 A MX 2015007193A MX 2015007193 A MX2015007193 A MX 2015007193A MX 2015007193 A MX2015007193 A MX 2015007193A
Authority
MX
Mexico
Prior art keywords
group
hydrogen
alkyl
amino
receptor ligands
Prior art date
Application number
MX2015007193A
Other languages
English (en)
Other versions
MX370354B (es
Inventor
Frank Osterkamp
Ulrich Reineke
Christiane Smerling
Christian Haase
Jan Ungewiss
Original Assignee
3B Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3B Pharmaceuticals Gmbh filed Critical 3B Pharmaceuticals Gmbh
Publication of MX2015007193A publication Critical patent/MX2015007193A/es
Publication of MX370354B publication Critical patent/MX370354B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a un compuesto de fórmula (I) en donde R1 se selecciona del grupo que consiste de hidrógeno, metilo y ciclopropilmetilo; AA-COOH es un aminoácido seleccionado del grupo que consiste de ácido 2-amino-2-adamantan-carboxílico, ciclohexilglicina y ácido 9-amino-biciclo [3.3.1] nonan-9-carboxílico; R2 se selecciona del grupo que consiste de alquilo de 1 a 6 átomos de carbono, cicloalquilo de 3 a 8 átomos de carbono, cicloalquilmetilo de 3 a 8 átomos de carbono, halógeno, nitro y trifluorometilo; ALK es alquilideno de 2 a 5 átomos de carbono; R3, R4 y R5 son cada uno y se seleccionan independientemente del grupo que consiste de hidrógeno y alquilo de 1 a 4 átomos de carbono con la condición de que uno de R3, R4 y R5 sea de la fórmula (II), en donde ALK' alquilideno de 2 a 5 átomos de carbono; R6 se selecciona del grupo que consiste de hidrógeno y alquilo de 1 a 4 átomos de carbono, y R7 se selecciona del grupo que consiste de H y una porción Efectora; o una sal farmacológicamente aceptable, solvato o un hidrato del mismo.
MX2015007193A 2012-12-07 2013-12-06 Ligando de receptor de neurotensina. MX370354B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12008208.6A EP2740726A1 (en) 2012-12-07 2012-12-07 Neurotensin receptor ligands
PCT/EP2013/003700 WO2014086499A1 (en) 2012-12-07 2013-12-06 Neurotensin receptor ligands

Publications (2)

Publication Number Publication Date
MX2015007193A true MX2015007193A (es) 2016-03-17
MX370354B MX370354B (es) 2019-12-10

Family

ID=47355771

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015007193A MX370354B (es) 2012-12-07 2013-12-06 Ligando de receptor de neurotensina.

Country Status (21)

Country Link
US (2) US10961199B2 (es)
EP (3) EP2740726A1 (es)
JP (2) JP6576828B2 (es)
KR (1) KR102290803B1 (es)
CN (2) CN104837819B9 (es)
AU (1) AU2013354422B2 (es)
BR (1) BR112015012530B1 (es)
CA (1) CA2893605C (es)
DK (2) DK3712131T3 (es)
ES (2) ES2941629T3 (es)
FI (1) FI3712131T3 (es)
HK (1) HK1210148A1 (es)
HU (2) HUE061839T2 (es)
IL (1) IL239080B (es)
MX (1) MX370354B (es)
PL (2) PL2928870T3 (es)
PT (2) PT2928870T (es)
RU (1) RU2671970C2 (es)
SG (2) SG11201503880YA (es)
WO (1) WO2014086499A1 (es)
ZA (1) ZA201503446B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2743781C2 (ru) * 2014-06-10 2021-02-25 3Б Фармасьютикалз Гмбх Конъюгат, содержащий лиганд рецепторов нейротензина, и его применение
EP2954933A1 (en) * 2014-06-10 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand
EP2954934A1 (en) * 2014-06-11 2015-12-16 3B Pharmaceuticals GmbH Conjugate comprising a neurotensin receptor ligand and use thereof
BR112018010535A2 (pt) * 2015-11-24 2018-11-13 Transfert Plus Sec compostos peptídicos e conjugados peptídicos para o tratamento de câncer por quimioterapia com mediação por um receptor
EP3279197A1 (en) * 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
CA3045466A1 (en) 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging
EA201991673A1 (ru) 2017-02-10 2020-01-17 Регенерон Фармасьютикалз, Инк. Меченные радиоактивным изотопом антитела к lag3 для иммуно-пэт-визуализации
JP7304846B2 (ja) 2017-07-24 2023-07-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｃｄ８抗体およびその使用
KR20220032079A (ko) * 2019-07-08 2022-03-15 쓰리비 파마슈티컬스 게엠베하 섬유모세포 활성화 단백질 리간드를 포함하는 화합물 및 그의 용도
CN111875667B (zh) * 2020-07-16 2021-12-21 南方科技大学 有机金属螯合物及其制备方法与应用、探针
JPWO2022085571A1 (es) * 2020-10-22 2022-04-28
CA3220010A1 (en) * 2021-05-13 2022-11-17 The General Hospital Corporation Molecular probes for in vivo detection of aldehydes
EP4355377A1 (en) * 2021-06-16 2024-04-24 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound, gemcitabine and nab-paclitaxel
EP4355325A1 (en) * 2021-06-16 2024-04-24 Fusion Pharmaceuticals Inc. Combination comprising a neurotensin receptor binding compound and folfirinox
WO2023141722A1 (en) * 2022-01-28 2023-08-03 Fusion Pharmaceuticals Inc. Ntsr1-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy
WO2023158802A1 (en) * 2022-02-18 2023-08-24 Full-Life Technologies U.S. Inc. Compounds and radioligands for targeting neurotensin receptor and uses thereof
WO2023215778A1 (en) * 2022-05-03 2023-11-09 The University Of North Carolina At Chapel Hill Development of ntsr targeted agents for imaging and therapy applications

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110321A (en) 1976-07-12 1978-08-29 Folkers Karl Synthetic tridecapeptide [Gln4 ]-neurotensin having hormonal activity
US4425269A (en) 1982-06-07 1984-01-10 Merck & Co., Inc. Metabolically protected analogs of neurotensin
US4439359A (en) 1982-07-02 1984-03-27 Merck & Co., Inc. Cyclic octapeptide analogs of neurotensin
US4885363A (en) 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5965107A (en) 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
CA2086453A1 (en) 1992-12-30 1994-07-01 Mcgill University Marker for neurotensin receptor
US5407916A (en) 1993-02-16 1995-04-18 Warner-Lambert Company Neurotensin mimetics as central nervous system agents
FR2711140B1 (fr) * 1993-10-12 1996-01-05 Sanofi Sa 1-Naphtylpyrazole-3-carboxamides substitués actifs sur la neurotensine, leur préparation, les compositions pharmaceutiques en contenant.
CA2183421A1 (en) 1994-02-18 1995-08-24 John Mertens Labelled peptide compounds
EP0820466A2 (en) 1995-04-04 1998-01-28 Advanced Bioconcept Inc. Fluorescent peptides
US6054557A (en) 1995-04-04 2000-04-25 Advanced Bioconcept (1994) Ltd. Fluorescent peptides
FR2732967B1 (fr) * 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
AU6352296A (en) 1995-07-20 1997-02-18 Advanced Bioconcept, Inc. Cell sorting with fluorescent peptides
IL131386A0 (en) 1997-02-03 2001-01-28 Mallinckrodt Medical Inc Method for the detection and localization of malignant human tumours
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
EP1067950B1 (en) 1998-04-10 2008-05-14 Mayo Foundation For Medical Education And Research Neo-tryptophan
EP1194444A2 (en) 1999-06-24 2002-04-10 BioSynthema Inc. Labeled neurotensin derivatives with improved resistance to enzymatic degradation
WO2005016141A1 (en) * 2003-07-09 2005-02-24 California Pacific Medical Center Remote detection of substance delivery to cells
US20060062729A1 (en) * 2004-09-09 2006-03-23 Carraway Robert E Enhanced ligand binding to neurotensin receptors
CA2676413A1 (en) * 2007-01-19 2008-07-31 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
EP2100900A1 (en) 2008-03-07 2009-09-16 Universitätsspital Basel Bombesin analog peptide antagonist conjugates
EP2334642B1 (en) * 2008-09-16 2014-01-01 The Regents Of The University Of California Simplified one-pot synthesis of [18f]sfb for radiolabeling
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
US8586043B2 (en) * 2009-01-07 2013-11-19 Inserm ( Institut National De La Sante Et De La Recherche Medicale) Methods for treating breast cancer with inhibitors of neurotensin activation of NTSR1
US9809624B2 (en) 2009-07-16 2017-11-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Neurotensin analogues for radioisotope targeting to neurotensin receptor-positive tumors
WO2011156557A2 (en) * 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor

Also Published As

Publication number Publication date
JP2019218375A (ja) 2019-12-26
PL3712131T3 (pl) 2023-05-02
BR112015012530B1 (pt) 2022-07-19
US10961199B2 (en) 2021-03-30
CA2893605C (en) 2021-08-10
EP2928870A1 (en) 2015-10-14
CN109320502B (zh) 2022-06-07
ES2795923T3 (es) 2020-11-25
CN104837819B (zh) 2018-12-07
RU2671970C2 (ru) 2018-11-08
AU2013354422A1 (en) 2015-05-28
HK1210148A1 (en) 2016-04-15
DK3712131T3 (da) 2023-03-20
SG10201704564QA (en) 2017-07-28
US20150299133A1 (en) 2015-10-22
EP2740726A1 (en) 2014-06-11
JP2016501238A (ja) 2016-01-18
EP3712131A1 (en) 2020-09-23
BR112015012530A2 (pt) 2017-09-12
JP7042776B2 (ja) 2022-03-28
MX370354B (es) 2019-12-10
KR102290803B1 (ko) 2021-08-18
CN104837819A (zh) 2015-08-12
DK2928870T3 (da) 2020-07-13
FI3712131T3 (fi) 2023-03-28
ES2941629T3 (es) 2023-05-24
IL239080B (en) 2019-06-30
PT3712131T (pt) 2023-04-04
PL2928870T3 (pl) 2020-09-21
CN104837819B9 (zh) 2019-07-09
EP2928870B1 (en) 2020-04-08
ZA201503446B (en) 2016-01-27
IL239080A0 (en) 2015-07-30
EP3712131B1 (en) 2023-02-01
RU2015127086A (ru) 2017-01-11
US20210087149A1 (en) 2021-03-25
PT2928870T (pt) 2020-05-29
HUE050388T2 (hu) 2020-11-30
AU2013354422B2 (en) 2018-03-15
HUE061839T2 (hu) 2023-08-28
WO2014086499A8 (en) 2014-12-31
WO2014086499A1 (en) 2014-06-12
SG11201503880YA (en) 2015-06-29
JP6576828B2 (ja) 2019-09-18
CN109320502A (zh) 2019-02-12
KR20150092300A (ko) 2015-08-12
CA2893605A1 (en) 2014-06-12

Similar Documents

Publication Publication Date Title
MX2015007193A (es) Ligando de receptor de neurotensina.
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
PH12016500169A1 (en) Polymorph of syk inhibitors
GEP201706728B (en) Noxious organism control agent
TN2018000106A1 (en) Farnesoid x receptor modulators
MX2016006336A (es) Compuestos pirazolopirimidina.
NZ703714A (en) 2-aminopyrazine derivatives as csf-1 r kinase inhibitors
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
MY172924A (en) Neprilysin inhibitors
MY150289A (en) Derivatives of indole-2-carboxamides and of azaindole-2-carboxamides substituted with a silanyl group, preparation thereof and therapeutic use thereof
MX2016007861A (es) Compuestos de ácido dimetilbenzoico.
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
NZ712352A (en) Novel inhibitors of glutaminyl cyclase
IN2012DN02556A (es)
MX2010002171A (es) Compuestos 8-azabiciclo[3.2.1] octil-2 hidroxibenzamida como antagonistas de los receptores opioides mu.
EA201401082A1 (ru) Фармацевтические препараты, содержащие антагонисты ccr3
BR112012031340A2 (pt) derivados de cianoquinolina
MX2013007938A (es) Compuesto biciclico novedoso o sal del mismo.
MX2016003422A (es) Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen.
MX2017005423A (es) Inhibidores de histona desacetilasa y sus usos en terapia.
GB201101517D0 (en) Receptor antagonists
MX341341B (es) Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90).
MY170262A (en) Dicarboxylic acid compound
TN2012000105A1 (en) Spirolactam derivatives and uses of same
MY149973A (en) 3-carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists

Legal Events

Date Code Title Description
FG Grant or registration